The TranspariMED organisation has published its latest, Europe-wide report on the transparency of clinical studies and drug trials conducted at universities, in which it highly commended MedUni Vienna's efforts, which have now resulted in over 90% of completed clinical trials being registered in public databases: "MedUni Vienna has become one of the leading players in the whole of Europe when it comes to study transparency. The university's strong commitment to transparency benefits patients and taxpayers alike," said Till Bruckner, founder of TranspariMED.
"MedUni Vienna has committed itself to transparency in clinical trials in its guidelines for good scientific practice. With support from the Clinical Trials Coordination Centre, a first important milestone has been reached: more than 90% of completed clinical drug trials are now registered in public databases and accessible to interested parties. In this way, MedUni Vienna is demonstrating its responsibility in the role of a European clinical research institution," emphasises Michael Wolzt from the Department of Clinical Pharmacology and Head of the Clinical Trials Coordination Centre at MedUni Vienna.
LINK to the latest report: https://www.transparimed.org/single-post/groningen-leiden.